Carlos H. Barrios

Porto Alegre, RS, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 213 publications

Decade of Progress: Ethical and Regulatory Approval Timelines for Cancer Clinical Trials in Brazil.

Decade of Progress: Ethical and Regulatory Approval Timelines for Cancer Clinical Trials in Brazil.

Journal: JCO global oncology

Published: August 13, 2026

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: May 21, 2026

Distinct CMR Phenotype in Alcoholic Cardiomyopathy: Greater Myocardial Fibrosis and Right Ventricular Dysfunction Compared with Idiopathic Dilated Cardiomyopathy.

Distinct CMR Phenotype in Alcoholic Cardiomyopathy: Greater Myocardial Fibrosis and Right Ventricular Dysfunction Compared with Idiopathic Dilated Cardiomyopathy.

Journal: Diagnostics (Basel, Switzerland)

Published: April 09, 2026

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

Journal: Breast (Edinburgh, Scotland)

Published: April 08, 2026

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Journal: Breast (Edinburgh, Scotland)

Published: April 08, 2026

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 24, 2026

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

Journal: NPJ breast cancer

Published: March 09, 2026

Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.

Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.

Journal: Clinical breast cancer

Published: February 26, 2026

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.

Journal: The oncologist

Published: January 22, 2026

H-score and ERBB2 mRNA refine identification of HER2-low and HER2-ultralow breast cancer.

H-score and ERBB2 mRNA refine identification of HER2-low and HER2-ultralow breast cancer.

Journal: Breast cancer research : BCR

Published: January 03, 2026

Independent Cancer Research in Low- and Middle-Income Countries: Why it matters and how to build it.

Independent Cancer Research in Low- and Middle-Income Countries: Why it matters and how to build it.

Journal: The oncologist

Published: December 21, 2025

Showing 1-12 of 213

Last Updated: 09/26/2026